Stockscreener 앱 받기
14.33
0.14%
0.02
Amicus Therapeutics Inc 주식(FOLD)의 최신 뉴스
Amicus Therapeutics, Inc. $FOLD Holdings Boosted by Stephens Investment Management Group LLC - MarketBeat
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025 - FinancialContent
Nordea Investment Management AB Makes New $7.84 Million Investment in Amicus Therapeutics, Inc. $FOLD - MarketBeat
FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? - Finviz
Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia - Yahoo Finance
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - Yahoo Finance
One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit - Yahoo Finance
Amicus Therapeutics stock hits 52-week high at 14.36 USD By Investing.com - Investing.com Nigeria
Amicus Therapeutics (NASDAQ:FOLD) Reaches New 1-Year HighHere's What Happened - MarketBeat
Amicus Therapeutics stock hits 52-week high at 14.36 USD - Investing.com
Aug Shorts: Is Amicus Therapeutics Inc. showing insider buyingWeekly Trade Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes - Finviz
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: 19.5% Revenue Growth and Potential Upside Attract Investors - DirectorsTalk Interviews
MDGL Secures Exclusive Global Right for MASH Treatment From PFE - Finviz
BioMarin Expands Rare Disease Portfolio With $4.8 Billion Amicus Acquisition - The Healthcare Technology Report.
BioMarin to acquire Amicus for $14.50 per share in cash, or $4.8B - MSN
Amicus Therapeutics : Legend (1) - marketscreener.com
Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum - Yahoo Finance
Peregrine Capital Management LLC Acquires 72,178 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Why Amicus Therapeutics Inc. stock remains undervalued - Улправда
Is Amicus Therapeutics (FOLD) Pricing Reflect Recent 45% Surge And DCF Upside Potential - Yahoo Finance
Halper Sadeh LLC Encourages THS, FOLD, REVG Shareholders to Contact the Firm to Discuss Their Rights - Sahm
Will Amicus Therapeutics Inc. stock benefit from sector rotationPortfolio Value Report & Entry Point Strategy Guides - ulpravda.ru
How Amicus Therapeutics Inc. stock performs in rising dollar environment2025 Key Highlights & Weekly High Momentum Picks - ulpravda.ru
Risk Off: Can Amicus Therapeutics Inc. stock deliver strong Q4 earningsQuarterly Risk Review & Daily Oversold Stock Bounce Ideas - ulpravda.ru
Why retail investors pile into Amicus Therapeutics Inc. stockWatch List & Technical Buy Zone Confirmations - ulpravda.ru
Buyback Watch: Will Amicus Therapeutics Inc. stock remain a Wall Street favoriteWeekly Gains Summary & Risk Controlled Stock Alerts - ulpravda.ru
How Amicus Therapeutics Inc. stock compares to industry benchmarksSell Signal & Low Drawdown Investment Strategies - ulpravda.ru
Can Amicus Therapeutics Inc. stock deliver strong Q4 earningsMarket Activity Report & Growth Focused Investment Plans - ulpravda.ru
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug - Yahoo Finance
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare-disease company with a presence in Philadelphia - MSN
San Gabriel Valley Tribune - FinancialContent
Amicus Therapeutics, Inc.Common Stock (NQ: FOLD - FinancialContent
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger-EKSO, FOLD, CWAN, and JHG - The Malaysian Reserve
Halper Sadeh LLC Encourages EKSO, FOLD, CWAN, JHG Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
HC Wainwright: BioMarin’s (BMRN) Amicus acquisition stabilizes cash flow while Voxzogo remains near-term driver - MSN
What analysts say about Amicus Therapeutics Inc stockValue Traps to Avoid & Big Gains Low Budget - earlytimes.in
Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase? - Finviz
Will Galafold Be Able to Aid FOLD's Top Line Heading Into Q4 Earnings? - sharewise.com
Amicus Therapeutics (NASDAQ:FOLD) Rating Lowered to "Hold" at Guggenheim - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Amicus Therapeutics Inc AM6 Stock Analysis and Forecast - earlytimes.in
BioMarin's $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance - FinancialContent
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025 - FinancialContent
H.C. Wainwright: BioMarin’s (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver - Insider Monkey
H.C. Wainwright: BioMarin's (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver - Finviz
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025 - FinancialContent
Amicus Therapeutics Earnings Notes - Trefis
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
BioMarin Acquiring Amicus — Both Great Companies, Only One Worth Buying Now (NASDAQ:BMRN) - Seeking Alpha
BioMarin to Acquire Amicus Therapeutics for $4.8B - Contract Pharma
Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday - Benzinga
FOLD: Analyst Downgrade and Price Target Adjustments | FOLD Stoc - GuruFocus
Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Lowered by Leerink Partners - MarketBeat
Leerink Downgrades Amicus Therapeutics to Market Perform From Outperform, Adjusts Price Target to $14.50 From $17 - MarketScreener
Leerink Partners downgrades Amicus Therapeutics stock on BioMarin acquisition By Investing.com - Investing.com UK
Analysts grow more bullish on BioMarin Pharmaceuticals Inc. (BMRN) after Amicus acquisition - MSN
Amicus Therapeutics, Inc. $FOLD Shares Acquired by Rice Hall James & Associates LLC - MarketBeat
Best Biotech Stocks To Watch TodayDecember 21st - MarketBeat
4.73%
0.92%
자본화:
|
볼륨(24시간):